Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HEPA | SC 13D | neutral | 5/10 | 🔒Gravitas Collective Corp. filed a Schedule 13D disclosing beneficial ownership of 25,000,000 shares of Hepion Pharmaceut | Oct 26, 2026 |
| JUNS | SC 13G/A | neutral | 2/10 | 🔒PharmAla Biotech Holdings Inc. filed an amendment to its Schedule 13G, confirming a 10.1% passive stake in Jupiter Neuro | Oct 26, 2026 |
| KRRO | INSIDER-BUY | bullish | 5/10 | 🔒Lynx1 Capital Management, a 10% owner of Korro Bio, purchased 12,175 shares at $9.68 for $118K in an open-market transac | Oct 26, 2026 |
| IRON | SC 13D/A | neutral | 3/10 | 🔒AI DMI LLC (Access Industries) filed Amendment No. 7 to its Schedule 13D for Disc Medicine, reporting a 6.6% beneficial | Oct 26, 2026 |
| KLRS | SC 13G | neutral | 3/10 | 🔒Coastlands Capital LP and related entities filed a Schedule 13G disclosing a 5.69% passive stake in Kalaris Therapeutics | Oct 26, 2026 |
| GRML | S-1 | neutral | 4/10 | 🔒Greenland Mines Ltd filed an S-1 registration statement to register 1,400,000 shares of common stock for resale by forme | Oct 26, 2026 |
| HOWL | S-4/A | bearish | 5/10 | 🔒Werewolf Therapeutics filed an S-4/A registration statement for a reverse merger with Ambros Therapeutics, where Ambros | Oct 26, 2026 |
| SKYE | PREM14A | bearish | 7/10 | 🔒Skye Bioscience (SKYE) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acquisition of | Oct 26, 2026 |
| WST | 8-K | neutral | 4/10 | 🔒West Pharmaceutical Services entered into a new $950 million unsecured credit agreement on October 26, 2026, consisting | Oct 26, 2026 |
| EQ | 8-K | bearish | 6/10 | 🔒Equillium dosed the first subject in a Phase 1 trial of EQ504, triggering a $20 million milestone closing under its Augu | Oct 26, 2026 |
| BOLD | 425 | neutral | 3/10 | 🔒Boundless Bio (BOLD) filed a Rule 425 communication in connection with its pending merger with Serapha Bio. The filing a | Oct 26, 2026 |
| ONCO | 8-K | neutral | 3/10 | 🔒Onconetix announced a second 1-for-10 reverse stock split, effective November 6, 2026, reducing outstanding shares from | Oct 26, 2026 |
| RLYB | 425 | neutral | 5/10 | 🔒Rallybio Corp declared an estimated $82.7 million special cash distribution ($13.56 per share) in connection with its pe | Oct 26, 2026 |
| RLYB | 8-K | neutral | 5/10 | 🔒Rallybio Corp's board declared a special cash distribution of approximately $82.7 million ($13.56 per share) to stockhol | Oct 26, 2026 |
| GLSI | DEFA14A | neutral | 2/10 | 🔒Greenwich LifeSciences filed a DEFA14A (additional definitive proxy soliciting materials) on the same day as its definit | Oct 26, 2026 |
| CRL | CLUSTER | neutral | 2/10 | 🔒Two CRL insiders sold a combined $9.16M in open-market sales, all under 10b5-1 trading plans. Director Foster's $8.41M s | Oct 26, 2026 |
| SAFX | SC 13D/A | bearish | 6/10 | 🔒EEME Energy SPV I, LLC and its managing member Majique Ladnier filed an amended Schedule 13D disclosing a maintained 38. | Oct 26, 2026 |
| TRAW | S-1 | bearish | 6/10 | 🔒Traws Pharma filed an S-1 registration statement to register up to 135,135,135 shares of common stock for resale by Roth | Oct 26, 2026 |
| MIRM | 8-K | bullish | 6/10 | 🔒Mirum Pharmaceuticals announced positive Phase 3 PROGRESS Cohort 2 results for ATEBRIOZ (zilurgisertib) in pediatric FOP | Oct 26, 2026 |
| LGVN | 8-K | neutral | 5/10 | 🔒Longeveron announced updated results from its ELPIS II Phase 2b trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| AEON | DEF 14A | neutral | 3/10 | 🔒AEON Biopharma is holding a special meeting on December 15, 2026 to vote on four proposals: (1) authorizing a reverse st | Oct 26, 2026 |
| SUPN | 8-K | neutral | 2/10 | 🔒Supernus Pharmaceuticals terminated its uncommitted demand revolving UBS Credit Line on October 20, 2026, in anticipatio | Oct 26, 2026 |
| CVSI | 8-K | neutral | 2/10 | 🔒CV Sciences settled its JAMS arbitration against former legal counsel, receiving $500,000 and mutually releasing all cla | Oct 26, 2026 |
| CPIX | 8-K | neutral | 5/10 | 🔒Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban as a treatmen | Oct 26, 2026 |
| SLBT | 6-K | neutral | 4/10 | 🔒SL Science Holding Ltd (SLBT) filed its unaudited H1 2026 financial results via Form 6-K, reporting revenue of $1.39M (u | Oct 26, 2026 |
| CTY | SC 13D | neutral | 5/10 | 🔒ARCH Venture Fund XII, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 13,692,507 s | Oct 26, 2026 |
| MCRB | 8-K | bearish | 5/10 | 🔒Seres Therapeutics CFO Marella Thorell resigned effective November 15, 2026, and will provide advisory services for an o | Oct 26, 2026 |
| GLSI | DEF 14A | neutral | 3/10 | 🔒Greenwich LifeSciences filed its definitive proxy statement for the 2026 annual meeting. The filing is routine: it propo | Oct 26, 2026 |
| CTY | SC 13G | neutral | 4/10 | 🔒Viking Global Investors LP and affiliated entities filed a Schedule 13G disclosing a passive 7% stake in City Therapeuti | Oct 26, 2026 |
| MEDP | 144 | neutral | 2/10 | 🔒Susan E. Burwig, an officer of Medpace Holdings, filed a Form 144 notice of intent to sell 16,060 shares of common stock | Oct 26, 2026 |
Page 1 of 334 Next »